The Cognition Group (TCG) has updated its hardware for the Signal Enhancement System (SES). This technological enhancement will allow patient interviews to be recorded and viewed in a more precise, higher quality format and will further improve international clinical trials.
Clinical trials in the Central Nervous System (CNS) have been riddled with human error as long as they have existed. Problems include inconsistent or biased ratings, patients with incorrect diagnoses participating in the study, or even rating of the wrong interview. All of these issues have decreased the signal in CNS clinical trials.
SES is a system that resolves these issues through interview quality control, study assessment standardization, and scale rating integrity at the investigating sites. The system, which has been used in CNS clinical trials for the last three years, not only ensures that interviews are conducted according to protocol, but also facilitates expert and consensus ratings.
Data presented at recent conferences show that the SES controls for raters' enrollment bias and expectancy bias while ensuring that patients with the correct diagnosis are entered into the study. It addresses in-study rater variance by identifying raters’ nonconformity to pre-set rating standards, consequently enhancing data quality. The technology's strength is based on more focused patient evaluation and controlled impact of inconsistent rater performance on trial outcomes.
Recently, TCG has updated all of its hardware that it distributes to sites by replacing all of its laptops with a newer model; adding a 180 degree, higher pixel motion-detecting camera; and including a USB microphone that can record conversation up to 50 feet away. “We are very excited about this update,” said Subhash Goswami, Chief Operating Officer of TCG. “SES has revolutionized the way in which CNS clinical trials are conducted. Updating the hardware allows us to further improve the industry standards and greatly reduce errors in clinical trials.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.